Method for determining content of impurities in linagliptin raw material

A technology of impurity content and API, applied in the field of biomedicine, can solve the problems affecting the quality of linagliptin products and the efficacy of linagliptin, and achieve the effects of quality control, good separation, and real measurement.

Active Publication Date: 2018-04-03
SUNSHINE LAKE PHARM CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, in the production process of linagliptin raw materials, impurities such as synthetic starting materials and i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining content of impurities in linagliptin raw material
  • Method for determining content of impurities in linagliptin raw material
  • Method for determining content of impurities in linagliptin raw material

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0056] Example 1

[0057] In this example, the inventor introduced in detail the development process of the method for determining the content of impurities in the linagliptin bulk drug.

[0058] 1.1 Determination of buffer salt type and pH value

[0059] Linagliptin contains a primary amine group. CAD software predicts that the pKa of its conjugate acid is as high as 10.0, which is relatively strong. Linagliptin also contains a number of basic groups, all of which are connected to more complex groups. The acidity and alkalinity are difficult to judge. It is necessary to select a buffer with a suitable pH value to ensure that the compound to be separated exists in a single form during the separation process, so as to achieve a single peak, a sharp peak shape, and a separation effect that reproduces the retention time. Therefore, at the initial stage of method development, the inventors investigated the separation effect of linagliptin and corresponding impurities under the same gra...

Example Embodiment

[0085] Example 2

[0086] In this example, the inventor investigated the system applicability and sensitivity of the method for determining the impurity content in the linagliptin bulk drug determined in Example 1, and introduced in detail how to base on the chromatographic conditions determined in Example 1. Under the chromatogram obtained, calculate the content of impurities.

[0087] 2.1 Preparation of related solutions

[0088] The diluent (blank solution) is: a mixed solution of acetonitrile: phase A=1:4;

[0089] Test solution: Take about 20 mg of the test substance, accurately weigh it, and place it in a 100mL volumetric flask. Use an appropriate amount of diluent to dissolve, sonicate and dilute to the mark. Shake well to obtain, and prepare 2 copies in parallel;

[0090] System suitability solution: Take about 4mg of impurity A reference substance, weigh it into a 100mL volumetric flask, accurately pipette 5mL of test solution 1 to the same 100mL volumetric flask, add diluent ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Wavelengthaaaaaaaaaa
Login to view more

Abstract

The invention provides a method for determining content of impurities in a linagliptin raw material. The method comprises the steps as follows: analyzing the linagliptin raw material with HPLC (high performance liquid chromatography) to obtain a chromatogram; determining the content of impurities in the linagliptin raw material on the basis of the chromatogram, wherein the HPLC adopts the following conditions: a chromatographic column is a chromatographic column YMC-PACK ODS-AM with the specification of 4.6*250 mm and 5 mu m, a detector is (diode array detector) DAD, the detection wavelength is 226 nm, the column temperature is 25 DEG C, a mobile phase A is a 10 mmol/L potassium dihydrogen phosphate buffer solution with the pH in a range of 3.0-5.0, a mobile phase B is acetonitrile, the flow speed is 1.0 mL/min, operation lasts for 10 min, and the elution gradient is shown in the description. With the adoption of the detection method, the content of impurities in the linagliptin raw material can be determined conveniently, accurately and sensitively, so that the quality of the linagliptin raw material can be effectively controlled.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular, the invention relates to a method for measuring the impurity content in linagliptin bulk drug. Background technique [0002] Type II diabetes is caused by insufficient secretion of insulin by the body's pancreatic beta cells or the insensitivity of target cells to insulin (insulin resistance), also known as non-insulin-dependent diabetes. Type II diabetes mostly occurs after the age of 35 to 40, accounting for more than 90% of diabetic patients. [0003] Linagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), and is an effective drug for treating type II diabetes. Its molecular structure is: It is easily soluble in methanol, slightly soluble in acetonitrile, and hardly soluble in water. [0004] However, in the production process of linagliptin API, impurities such as synthetic starting materials and intermediates will be introduced, which will affect the quality of linaglipti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/34G01N30/26
CPCG01N30/02G01N30/26G01N30/34
Inventor 舒伟虎杨成刘国柱
Owner SUNSHINE LAKE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap